Please assess the completion status of the following clinical trial:

Trial Title: DP-b99 in the Treatment of Acute High-risk Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject.~* Age 18 years or higher.~* First in a lifetime episode of acute pancreatitis.~* Diagnosis of acute pancreatitis based on 2 of the following 3 criteria: (1) typical upper abdominal pain; (2) elevation of serum amylase and/or lipase at least 3 times the upper limit of normal; (3) contrast-material enhanced CT scan or abdominal sonogram demonstrating changes of acute pancreatitis~* History supporting alcoholic, hypertriglyceridemic or biliary etiology of the current pancreatitis episode (for biliary pancreatitis, a sonogram must exclude a stone obstruction at the time of study screening).~* BISAP score of 3 or higher~* Study treatment initiation is possible within 48 h of symptom onset~* Ability to provide informed consent~Exclusion Criteria:~* Drug-induced, viral, hereditary or post-ERCP pancreatitis.~* Recurrent episode of pancreatitis.~* CT evidence of pancreatic necrosis at study entry.~* Imaging evidence of physical obstruction of the common bile duct at study entry; e.g. for abdominal sonogram, stone(s) in the common bile duct or common bile duct having diameter less than 6 mm (above 80 years, less than 8 mm) with gallbladder in situ.~* Severe chronic renal failure (Modification of Diet in Renal Disease formula 30 mL/min or dependency on renal dialysis).~* High likelihood for an invasive intra-biliary tract intervention (e.g. ERCP) in the coming week.~* Class II or greater New York Heart Association heart failure.~* Oxygen-dependent chronic obstructive pulmonary disease (COPD).~* Cirrhosis of the liver.~* Severe anemia (hemoglobin less than 8 g/dL).~* Hematocrit below 35 % or above 45 % at study entry (fluids may be administered to correct the hematocrit before randomisation as long as study treatment starts within 48 hours of symptoms onset).~* Serum alanine aminotransferase above 250 IU/L at study entry.~* Clinical suspicion of ascending cholangitis at study entry.~* Active gastrointestinal bleeding.~* Current malignancy not in remission (other than basal cell carcinoma of skin).~* Altered mental status.~* Current breastfeeding or pregnancy.~* Female of childbearing potential (less than 2 years postmenopausal or not surgically sterilized) who is not willing to use adequate and effective birth control measures~* Known hypersensitivity to any component of the investigational product.~* Dependent relationship with the investigator or the sponsor.~* Participation in an investigational drug study during this clinical trial or within 30 days prior to start of this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DP-b99 (Type: EXPERIMENTAL): Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).